Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors

Prostate cancer (PCA) and lower urinary tract symptoms (LUTS) associated with aging and benign prostatic hyperplasia are ubiquitous in aging men. PCA has a high prevalence, causes considerable morbidity when metastatic, and is the third most common cause of cancer death in men (1). LUTS adversely affects quality of life and may result in recurrent infections and urinary retention, leading to morbidity and mortality among older men.

http://ift.tt/2tIXZAA